172 related articles for article (PubMed ID: 24231253)
1. 6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer.
Shen H; Morrison CD; Zhang J; Underwood W; Yang N; Frangou C; Eng K; Head K; Bollag RJ; Kavuri SK; Rojiani AM; Li Y; Yan L; Hill A; Woloszynska-Read A; Wang J; Liu S; Trump DL; Candace JS
Oncotarget; 2013 Nov; 4(11):2124-34. PubMed ID: 24231253
[TBL] [Abstract][Full Text] [Related]
2. Sox4 Expression Confers Bladder Cancer Stem Cell Properties and Predicts for Poor Patient Outcome.
Shen H; Blijlevens M; Yang N; Frangou C; Wilson KE; Xu B; Zhang Y; Zhang L; Morrison CD; Shepherd L; Hu Q; Zhu Q; Wang J; Liu S; Zhang J
Int J Biol Sci; 2015; 11(12):1363-75. PubMed ID: 26681916
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification.
Hurst CD; Tomlinson DC; Williams SV; Platt FM; Knowles MA
Oncogene; 2008 Apr; 27(19):2716-27. PubMed ID: 18037967
[TBL] [Abstract][Full Text] [Related]
4. Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer.
Wu Q; Hoffmann MJ; Hartmann FH; Schulz WA
Mol Cancer; 2005 May; 4(1):16. PubMed ID: 15876350
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of potential target genes of the 6p22.3-amplicon in urinary bladder cancer].
Oeggerli M; Schraml P; Novotny H; Sauter G; Simon R
Verh Dtsch Ges Pathol; 2005; 89():219-24. PubMed ID: 18035695
[TBL] [Abstract][Full Text] [Related]
6. E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer.
Oeggerli M; Schraml P; Ruiz C; Bloch M; Novotny H; Mirlacher M; Sauter G; Simon R
Oncogene; 2006 Oct; 25(49):6538-43. PubMed ID: 16953223
[TBL] [Abstract][Full Text] [Related]
7. Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4.
Bellmunt J
Biomedicines; 2018 Aug; 6(3):. PubMed ID: 30072631
[TBL] [Abstract][Full Text] [Related]
8. Amplification and overexpression of E2F3 in human bladder cancer.
Feber A; Clark J; Goodwin G; Dodson AR; Smith PH; Fletcher A; Edwards S; Flohr P; Falconer A; Roe T; Kovacs G; Dennis N; Fisher C; Wooster R; Huddart R; Foster CS; Cooper CS
Oncogene; 2004 Feb; 23(8):1627-30. PubMed ID: 14716298
[TBL] [Abstract][Full Text] [Related]
9. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
[TBL] [Abstract][Full Text] [Related]
10. Detailed marker chromosome analysis in cell line U-BLC1, established from transitional-cell carcinoma of the bladder.
Bruch J; Wöhr G; Brüderlein S; Barbi G; Wolter H; Dixkens C; Mattfeldt T; Möller P; Paiss T; Hautmann R; Vogel W; Hameister H
Int J Cancer; 1999 Mar; 80(6):903-10. PubMed ID: 10074925
[TBL] [Abstract][Full Text] [Related]
11. Molecular cytogenetic alterations associated with rapid tumor cell proliferation in advanced urinary bladder cancer.
Tomovska S; Richter J; Süess K; Wagner U; Rozenblum E; Gasser TC; Moch H; Mihatsch MJ; Sauter G; Schraml P
Int J Oncol; 2001 Jun; 18(6):1239-44. PubMed ID: 11351257
[TBL] [Abstract][Full Text] [Related]
12. Detailed Analysis of Focal Chromosome Arm 1q and 6p Amplifications in Urothelial Carcinoma Reveals Complex Genomic Events on 1q, and SOX4 as a Possible Auxiliary Target on 6p.
Eriksson P; Aine M; Sjödahl G; Staaf J; Lindgren D; Höglund M
PLoS One; 2013; 8(6):e67222. PubMed ID: 23825644
[TBL] [Abstract][Full Text] [Related]
13. Delineation of the 6p22 amplification unit in urinary bladder carcinoma cell lines.
Bruch J; Schulz WA; Häussler J; Melzner I; Brüderlein S; Möller P; Kemmerling R; Vogel W; Hameister H
Cancer Res; 2000 Aug; 60(16):4526-30. PubMed ID: 10969802
[TBL] [Abstract][Full Text] [Related]
14. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer.
Oeggerli M; Tomovska S; Schraml P; Calvano-Forte D; Schafroth S; Simon R; Gasser T; Mihatsch MJ; Sauter G
Oncogene; 2004 Jul; 23(33):5616-23. PubMed ID: 15122326
[TBL] [Abstract][Full Text] [Related]
15. DNA copy number alterations and PPARG amplification in a patient with multifocal bladder urothelial carcinoma.
Conconi D; Panzeri E; Redaelli S; Bovo G; Volante M; Viganò P; Strada G; Dalprà L; Bentivegna A
BMC Res Notes; 2012 Oct; 5():607. PubMed ID: 23114535
[TBL] [Abstract][Full Text] [Related]
16. KIAA1096, a gene on chromosome 1q, is amplified and overexpressed in bladder cancer.
Huang WC; Taylor S; Nguyen TB; Tomaszewski JE; Libertino JA; Malkowicz SB; McGarvey TW
DNA Cell Biol; 2002 Oct; 21(10):707-15. PubMed ID: 12443540
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas.
Kunze E; Wendt M; Schlott T
Int J Mol Med; 2006 Oct; 18(4):547-57. PubMed ID: 16964403
[TBL] [Abstract][Full Text] [Related]
18. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.
Coogan CL; Estrada CR; Kapur S; Bloom KJ
Urology; 2004 Apr; 63(4):786-90. PubMed ID: 15072912
[TBL] [Abstract][Full Text] [Related]
19. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
20. Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells.
Olsson AY; Feber A; Edwards S; Te Poele R; Giddings I; Merson S; Cooper CS
Oncogene; 2007 Feb; 26(7):1028-37. PubMed ID: 16909110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
